Historique du chiffre d'affaires, des bénéfices et des flux de trésorerie d'après les états financiers officiels.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Voir les graphiques interactifs et les états complets → Modèle de valorisation (DCF) →
| Compte de résultat | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiffre d'affaires total | $68M | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | $31M | $8M | $4M | $3M | $82M | $12M | $14M | $3M |
| Bénéfice brut | $54M | $78M | ($321M) | ($323M) | ($146M) | ($90M) | ($41M) | ($59M) | ($58M) | ($77M) | $47M | ($18M) | $3M | ($19M) | ($28M) | $4M | $3M | $82M | $12M | $14M | $3M |
| Marge brute % | 79.4% | 88.5% | -1737.2% | -4284.1% | -154.6% | -127.1% | -73.7% | -220.5% | -183.0% | -575.5% | 43.7% | -61.9% | 5.4% | -61.4% | -371.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Résultat opérationnel (EBIT) | ($708M) | ($612M) | ($536M) | ($496M) | ($324M) | ($186M) | ($94M) | ($99M) | ($89M) | ($113M) | $19M | ($37M) | ($15M) | ($34M) | ($39M) | ($48M) | ($50M) | $26M | ($59M) | ($56M) | ($61M) |
| Marge opérationnelle % | -1041.2% | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | -110.6% | -517.3% | -1199.1% | -1926.1% | 32.0% | -475.7% | -414.7% | -1961.6% |
| Résultat net | ($894M) | ($785M) | ($590M) | ($526M) | ($389M) | ($215M) | ($127M) | ($122M) | ($106M) | ($128M) | $16M | ($38M) | ($15M) | ($34M) | ($42M) | ($48M) | ($49M) | $25M | ($56M) | ($49M) | ($57M) |
| Marge nette % | -1314.7% | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | -110.0% | -551.4% | -1196.5% | -1912.6% | 30.1% | -453.9% | -358.9% | -1826.5% |
| EBITDA | — | ($775M) | ($493M) | ($457M) | ($329M) | ($176M) | ($87M) | ($93M) | ($83M) | ($109M) | $19M | ($37M) | ($14M) | ($33M) | ($40M) | ($47M) | ($48M) | $27M | ($53M) | ($45M) | ($54M) |
| Bénéfice par action (EPS) | $-7.21 | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | $-2.11 | $-1.95 | $-2.59 | $0.39 | $-0.97 | $-0.41 | $-1.24 | $-2.30 | $-4.06 | $-4.61 | $2.54 | $-6.85 | $-6.16 | $-9.36 |
| Actions en circulation (M) | — | 120M | 112M | 97M | 90M | 77M | 65M | 58M | 54M | 49M | 43M | 39M | 36M | 27M | 18M | 12M | 11M | 10M | 8M | 8M | 6M |
Source : rapports publics de la société (SEC). Vérifiez sur SEC EDGAR avant de vous fier à tout chiffre.
Bilans, flux de trésorerie, données trimestrielles et ratios complets dans le visualiseur interactif de CYTK. /companies/us/CYTK
Les informations de ce site sont fournies à des fins éducatives et informatives uniquement ; elles ne constituent pas un conseil en investissement. Aucun objectif de cours ni recommandation n'est publié.
About TickerBase · Data methodology & sources · Privacy · Terms